Corvus Pharmaceuticals Inc (CRVS)
1.92
+0.19
(+10.98%)
USD |
NASDAQ |
May 03, 16:00
2.05
+0.13
(+6.77%)
After-Hours: 20:00
Corvus Pharmaceuticals Enterprise Value: 67.01M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 67.01M |
| May 02, 2024 | 57.69M |
| May 01, 2024 | 51.80M |
| April 30, 2024 | 48.86M |
| April 29, 2024 | 50.33M |
| April 26, 2024 | 43.96M |
| April 25, 2024 | 45.43M |
| April 24, 2024 | 46.90M |
| April 23, 2024 | 47.88M |
| April 22, 2024 | 43.47M |
| April 19, 2024 | 41.50M |
| April 18, 2024 | 42.00M |
| April 17, 2024 | 39.54M |
| April 16, 2024 | 44.94M |
| April 15, 2024 | 44.94M |
| April 12, 2024 | 47.88M |
| April 11, 2024 | 49.35M |
| April 10, 2024 | 46.90M |
| April 09, 2024 | 52.78M |
| April 08, 2024 | 56.71M |
| April 05, 2024 | 58.67M |
| April 04, 2024 | 55.73M |
| April 03, 2024 | 58.67M |
| April 02, 2024 | 64.06M |
| April 01, 2024 | 64.06M |
| Date | Value |
|---|---|
| March 28, 2024 | 60.14M |
| March 27, 2024 | 60.63M |
| March 26, 2024 | 59.16M |
| March 25, 2024 | 59.16M |
| March 22, 2024 | 60.63M |
| March 21, 2024 | 63.08M |
| March 20, 2024 | 63.57M |
| March 19, 2024 | 68.97M |
| March 18, 2024 | 66.02M |
| March 15, 2024 | 66.02M |
| March 14, 2024 | 65.04M |
| March 13, 2024 | 70.93M |
| March 12, 2024 | 71.91M |
| March 11, 2024 | 71.42M |
| March 08, 2024 | 76.81M |
| March 07, 2024 | 84.66M |
| March 06, 2024 | 78.28M |
| March 05, 2024 | 76.32M |
| March 04, 2024 | 78.77M |
| March 01, 2024 | 79.76M |
| February 29, 2024 | 82.70M |
| February 28, 2024 | 85.64M |
| February 27, 2024 | 88.58M |
| February 26, 2024 | 85.64M |
| February 23, 2024 | 88.09M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-26.95M
Minimum
Mar 16 2020
295.39M
Maximum
Sep 21 2021
36.53M
Average
33.26M
Median
Sep 03 2020
Enterprise Value Benchmarks
| Cyclacel Pharmaceuticals Inc | -0.7414M |
| Arbutus Biopharma Corp | 362.27M |
| Oragenics Inc | 3.216M |
| Relmada Therapeutics Inc | 14.72M |
| MAIA Biotechnology Inc | 60.36M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.653M |
| Total Expenses (Quarterly) | 5.651M |
| EPS Diluted (Quarterly) | -0.13 |
| Earnings Yield | -29.17% |